ALLMedicine™ Burkitt Lymphoma Center
Research & Reviews 757 results
https://doi.org/10.1182/bloodadvances.2022007475
Blood Advances; Ferreri AJM, Angelillo P et. al.
May 18th, 2022 - Patients with aggressive B-cell lymphoma and MYC rearrangement at FISH exhibit poor outcome after R-CHOP. In the last decade, 68 patients with Burkitt lymphoma (BL; n=46) or high-grade B-cell lymphoma (single, double or triple hit; HGBCL; n=22) we...
https://clinicaltrials.gov/ct2/show/NCT04933617
May 13th, 2022 - Background: Burkitt Lymphoma (BL) is a highly aggressive B cell lymphoma that often involves the bone marrow and central nervous system (CNS) Frontline therapy cures 80-85% of adults with BL but patients with CNS involvement or those who relapse a...
https://doi.org/10.1002/eji.202249820
European Journal of Immunology; Summerauer AM, Jäggi V et. al.
May 4th, 2022 - Endemic Burkitt lymphoma (eBL) is characterized by an oncogenic IGH/c-MYC translocation and Epstein-Barr virus (EBV) positivity, and is epidemiologically linked to Plasmodium falciparum malaria. Both EBV and malaria are thought to contribute to eB...
https://doi.org/10.3324/haematol.2021.280557
Haematologica Bomken S, Enshaei A et. al.
Apr 30th, 2022 - Rarely, immunophenotypically immature B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) carries an immunoglobulin-MYC rearrangement (IG-MYC-r). This can result in diagnostic confusion with Burkitt lymphoma/leukaemia and use of unproven indi...
https://doi.org/10.3324/haematol.2021.280543
Haematologica Kim M, Hwang HS et. al.
Apr 1st, 2022 - Not available.
Guidelines 2 results
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.
Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...
https://doi.org/10.1016/j.clon.2016.09.004
Clinical Oncology (Royal College of Radiologists (Great B... Prica A, Baldassarre F et. al.
Oct 18th, 2016 - Rituximab is the first monoclonal antibody to be approved for use by the US Food and Drug Administration in cancer. Its role in the treatment of non-Hodgkin lymphoma, including chronic lymphocytic leukaemia (CLL), has evolved significantly. We aim...
Drugs 1 results see all →
Clinicaltrials.gov 14 results
https://clinicaltrials.gov/ct2/show/NCT04933617
May 13th, 2022 - Background: Burkitt Lymphoma (BL) is a highly aggressive B cell lymphoma that often involves the bone marrow and central nervous system (CNS) Frontline therapy cures 80-85% of adults with BL but patients with CNS involvement or those who relapse a...
https://clinicaltrials.gov/ct2/show/NCT03620578
Mar 24th, 2022 - The dismal prognosis of DH-DLBCL patients following standard therapy with R-CHOP (overall survival at 2 years 35% for MYC+ vs 61% for MYC- patients) justifies upfront new treatment approaches. Attempts have been made to improve prognosis of DH-DLB...
https://clinicaltrials.gov/ct2/show/NCT03677128
Mar 22nd, 2022 - Each year, approximately 220,000 children globally are newly diagnosed with cancer. Over 85% of these new diagnoses are made in low- and middle-income countries (LMICs). Survival rates in LMICs are 5-25% compared to 80% in high-income countries (H...
https://clinicaltrials.gov/ct2/show/NCT03864419
Mar 10th, 2022 - OUTLINE: Open-label Phase I study characterizing the safety, tolerability, and activity of subcutaneous rituximab hyaluronidase (sqR) alone (KSHV-MCD), or combined with local standard of care chemotherapy (BL or DLBCL), in 2 age-based cohorts of p...
https://clinicaltrials.gov/ct2/show/NCT05206357
Jan 25th, 2022 - The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). Initial treatment cures 90% - 95% of children with these malignancies, leaving a very small population of rela...
News 38 results
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types
Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....
https://www.onclive.com/view/nccn-guidelines-set-new-pace-for-pediatric-all
Jan 3rd, 2022 - Patrick Brown, MD With the recent publication of an inaugural set of guidelines for treatment of pediatric acute lymphoblastic leukemia (ALL), the National Comprehensive Cancer Network (NCCN) seeks to introduce standards to a branch of care long ...
https://www.medscape.com/viewarticle/964124
Dec 3rd, 2021 - The US Food and Drug Administration yesterday approved rituximab (Rituxan) in combination with chemotherapy for pediatric patients (age 6 months to <18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (...
https://www.onclive.com/view/dr-noy-on-the-rationale-to-evaluate-devimistat-in-burkitt-lymphoma
Oct 6th, 2021 - Ariela Noy, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the rationale to evaluate devimistat (CPI-613) in patients with either relapsed/refractory Burkitt lymphoma/leukemia or high-grade B-cell lymphoma. Patients...
https://www.onclive.com/view/polatuzumab-vedotin-plus-r-chp-significantly-improves-pfs-over-r-chop-in-dlbcl
Aug 10th, 2021 - Polatuzumab vedotin-piiq (Polivy) in combination with rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) resulted in a statistically significant and clinically meaningful improvement in progression-free survival (PFS) vs ri...
